Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Anticoagulant Reversal Drugs Market, By Product
7.1. Anticoagulant Reversal Drugs Market, by Product Type, 2020-2030
7.1.1. Prothrombin Complex Concentrates
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Phytonadione
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Andexanet Alfa
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. Idarucizumab
7.1.4.1. Market Revenue and Forecast (2016-2030)
7.1.5. Protamine
7.1.5.1. Market Revenue and Forecast (2016-2030)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Anticoagulant Reversal Drugs Market, By Distribution Channel
8.1. Anticoagulant Reversal Drugs Market, By Distribution Channel, 2020-2030
8.1.1. Hospital Pharmacy
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Retail Pharmacy
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Online Pharmacy
8.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Anticoagulant Reversal Drugs Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Product (2016-2030)
9.1.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Product (2016-2030)
9.1.3.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Product (2016-2030)
9.1.4.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Product (2016-2030)
9.2.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Product (2016-2030)
9.2.3.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Product (2016-2030)
9.2.4.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Product (2016-2030)
9.2.5.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Product (2016-2030)
9.2.6.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Product (2016-2030)
9.3.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Product (2016-2030)
9.3.3.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Product (2016-2030)
9.3.4.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Product (2016-2030)
9.3.5.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Product (2016-2030)
9.3.6.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Product (2016-2030)
9.4.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Product (2016-2030)
9.4.3.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Product (2016-2030)
9.4.4.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Product (2016-2030)
9.4.5.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Product (2016-2030)
9.4.6.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Product (2016-2030)
9.5.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Product (2016-2030)
9.5.3.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Product (2016-2030)
9.5.4.2. Market Revenue and Forecast, By Distribution Channel (2016-2030)
Chapter 10. Company Profiles
10.1. Portola Pharmaceuticals
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Boehringer Ingelheim
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. CSL Behring
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Bausch Health Companies Inc.
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Octapharma AG
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Dr. Reddy's Laboratories
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. AMAG Pharmaceuticals, Inc.
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Pfizer, Inc.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. SGPharma Pvt. Ltd.
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Alps Pharmaceutical Ind. Co., Ltd.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
10.10.5. Recent Initiatives
10.11. Fresenius Kabi AG
10.11.1. Company Overview
10.11.2. Product Offerings
10.11.3. Financial Performance
10.11.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms